Executive leadership at Tevogen Bio Holdings.
Board of directors at Tevogen Bio Holdings.
Research analysts covering Tevogen Bio Holdings.
Recent press releases and 8-K filings for TVGN.
Tevogen Bio Holdings announces 2025 platform scalability and multi-indication T cell pipeline expansion
TVGN
New Projects/Investments
- Tevogen Bio Holdings advanced its proprietary ExacTcell™ platform in 2025, which increased laboratory yields of target-specific cytotoxic T lymphocytes (CTLs) to support efficient clinical supply and future manufacturing.
- The company expanded its cytotoxic T lymphocyte (CTL) pipeline across multiple viral and oncology indications, including completing T cell target identification for five additional HLA restrictions for its SARS-CoV-2 product and advancing preclinical activities for therapies targeting Epstein-Barr virus (EBV) associated lymphomas, chronic hepatitis B, and Human Papilloma Virus (HPV) related cancers.
- Tevogen also progressed its strategy to establish in-house GMP cell therapy manufacturing capabilities during 2025.
Jan 12, 2026, 2:00 PM
Tevogen Bio Holdings Recognized on 2025 NJBIZ Power List with Multi-Billion-Dollar Revenue Outlook
TVGN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Tevogen Bio Holdings (Nasdaq: TVGN) has been named to the 2025 New Jersey Power List by NJBIZ, recognizing its influence on New Jersey’s economic and innovation landscape.
- NJBIZ highlighted Tevogen’s pioneering ExacTcell™ platform, advancing pipeline in infectious diseases, oncology, and neurology, and its internally developed PredicTcell™ AI technology.
- The company has a previously projected near-term commercial potential, including an anticipated ~$1 billion in first-year specialty-care revenue and a cumulative five-year forecast of $18–22 billion.
- Tevogen is expanding its operations in New Jersey, including a 17,428-square-foot manufacturing facility and a new headquarters that more than doubles its prior footprint.
Dec 8, 2025, 7:50 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more